OncoMatch/Clinical Trials/NCT07775508
In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma
Is NCT07775508 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies SL1617 for b-cell lymphoma.
Treatment: SL1617 — This Phase 1, open-label, single-arm, dose-escalation study is designed to evaluate the safety and tolerability of SL1617 Injection in patients with relapsed or refractory B-cell lymphoma. SL1617 is an investigational in vivo CAR T-cell immunotherapy targeting CD19 and CD20, utilizing an engineered lentiviral vector to generate functional CAR-T cells in vivo without the need for ex vivo cell processing or lymphodepletion. Participants will receive a single intravenous infusion of SL1617 using a traditional 3+3 dose-escalation design. The planned starting dose is 1.0 × 10\^9 transducing units (TU), followed by dose levels of 3.0 × 10\^9 TU and 6.0 × 10\^9 TU. Dose escalation will be guided by the occurrence of dose-limiting toxicities (DLTs).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 expression
Required: CD20 expression
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: systemic therapy (anti-CD20 monoclonal antibody, anthracycline-containing chemotherapy) — first-line
first-line systemic therapy (which must include an anti-CD20 monoclonal antibody and an anthracycline-containing chemotherapy regimen)
Cannot have received: allogeneic hematopoietic stem cell transplantation
previously undergone allogeneic hematopoietic stem cell transplantation
Cannot have received: solid organ allogeneic transplantation
previously undergone solid organ allogeneic transplantation
Cannot have received: allogeneic cell therapy
previously undergone allogeneic cell therapy
Lab requirements
Blood counts
Absolute neutrophil count ≥1×10^9/L, platelet count ≥75×10^9/L, hemoglobin ≥60g/L
Kidney function
Creatinine clearance ≥60 mL/min
Liver function
ALT and AST ≤2.5×ULN, total bilirubin ≤1.5×ULN
Cardiac function
Ejection fraction ≥50%, no pericardial effusion on echocardiography, no significant ECG abnormalities
Adequate renal, hepatic, cardiac, and pulmonary function, defined as follows: Creatinine clearance (estimated by the Cockcroft-Gault formula) ≥60 mL/min; Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST)≤2.5×upper limit of normal (ULN), total bilirubin≤1.5×ULN; Cardiac ejection fraction≥50%, no pericardial effusion on echocardiography, and no significant abnormalities on electrocardiogram (ECG); No clinically significant pleural effusion, and oxygen saturation >92% on room air at baseline.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07775508 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic hematopoietic stem cell transplantation, solid organ allogeneic transplantation, allogeneic cell therapy disqualifies patients from enrollment.
Does this trial require CD19?
Yes, CD19 expression is a required biomarker for enrollment.
Does this trial require CD20?
Yes, CD20 expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages